We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
Read MoreHide Full Article
We expect AbbVie Inc. (ABBV - Free Report) to beat expectations when it reports first-quarter 2018 results on Apr 26, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.78%.
Shares of AbbVie have marginally outperformed the industry so far this year. While the stock has declined 4.1%, the industry has decreased 4.3%.
Notably, AbbVie’s earnings history is quite impressive with the pharmaceuticals company having outpaced estimates in all the last four quarters with an average beat of 1.81%.
Let’s see, how things are shaping up for the company this quarter.
Factors to Consider
AbbVie expects first-quarter 2018 earnings in the range of $1.77-$1.79 per share. Revenues are estimated to grow in a mid-teen range on an operational basis. Foreign exchange is anticipated to gain a 3% favorable impact on sales in the period to be reported.
The company’s key drug, Humira, is likely to remain a key growth driver in the first quarter, backed by strong demand trends for the drug. AbbVie expects Humira sales to reflect a rise in the low-teens band in the imminent earnings release while internationally, the growth rate is projected in a mid-single-digit range, operationally. The Zacks Consensus Estimate for Humira is pegged at $4.7 billion.
Significantly, on first-quarter conference call, investors’ focus will also be on the performance level as well as the label expansion updates of AbbVie’s another cancer drug, Imbruvica. The drug has been recording strong sales since the past few quarters, a trend that we expect to continue even in the quarter to be reported. The Zacks Consensus Estimate for Imbruvica stands at $759 million.
Other drugs, namely Duopa and Creon are also likely to maintain an encouraging performance in the soon-to-be-reported quarter.
However, AbbVie’s Hepatitis C virus (HCV) treatment, Viekira, will continue to see declining sales, affected by an intense pricing and competitive pressure in the HCV market.
Moreover, in March 2018, AbbVie’s rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study, evaluating it in third-line therapy for later small cell lung cancer (SCLC). On first-quarter conference call, we expect management to provide updates on the same.
Notably, AbbVie’s eight-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret, secured an approval in the United States, EU, Canada as well as Japan in the second half of 2017. Importantly, Mavyret recorded $500 million global sales last year. The initial uptake of the drug has been commendable and we expect its higher sales in the first quarter as well.
Earnings Whispers
Our proven model shows that the stock is likely to beat on earnings this quarter as it has the right combination of the two key ingredients — a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen.
Zacks ESP: AbbViehas an Earnings ESP of +0.06%. The Zacks Consensus Estimate is $1.80 per share. A positive ESP indicates a likely earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: AbbViehas a Zacks Rank #3, which increases the predictive power of ESP and together with a positive ESP, chances of the stock beating estimates in its upcoming release are always pegged higher.
We caution against the Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are a couple of other health care stocks worth considering with the right combination of elements to also surpass estimates this time around:
Bristol-Myers Squibb Company (BMY - Free Report) is scheduled to report earnings on Apr 26. The company has an Earnings ESP of +0.82% and a Zacks Rank of 3.
Celgene Corporation is slated to announce financial figures on May 4. The company has an Earnings ESP of +0.63% and is a Zacks #3 Ranked player.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
We expect AbbVie Inc. (ABBV - Free Report) to beat expectations when it reports first-quarter 2018 results on Apr 26, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.78%.
Shares of AbbVie have marginally outperformed the industry so far this year. While the stock has declined 4.1%, the industry has decreased 4.3%.
Notably, AbbVie’s earnings history is quite impressive with the pharmaceuticals company having outpaced estimates in all the last four quarters with an average beat of 1.81%.
Let’s see, how things are shaping up for the company this quarter.
Factors to Consider
AbbVie expects first-quarter 2018 earnings in the range of $1.77-$1.79 per share. Revenues are estimated to grow in a mid-teen range on an operational basis. Foreign exchange is anticipated to gain a 3% favorable impact on sales in the period to be reported.
The company’s key drug, Humira, is likely to remain a key growth driver in the first quarter, backed by strong demand trends for the drug. AbbVie expects Humira sales to reflect a rise in the low-teens band in the imminent earnings release while internationally, the growth rate is projected in a mid-single-digit range, operationally. The Zacks Consensus Estimate for Humira is pegged at $4.7 billion.
Significantly, on first-quarter conference call, investors’ focus will also be on the performance level as well as the label expansion updates of AbbVie’s another cancer drug, Imbruvica. The drug has been recording strong sales since the past few quarters, a trend that we expect to continue even in the quarter to be reported. The Zacks Consensus Estimate for Imbruvica stands at $759 million.
Other drugs, namely Duopa and Creon are also likely to maintain an encouraging performance in the soon-to-be-reported quarter.
However, AbbVie’s Hepatitis C virus (HCV) treatment, Viekira, will continue to see declining sales, affected by an intense pricing and competitive pressure in the HCV market.
Moreover, in March 2018, AbbVie’s rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study, evaluating it in third-line therapy for later small cell lung cancer (SCLC). On first-quarter conference call, we expect management to provide updates on the same.
Notably, AbbVie’s eight-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret, secured an approval in the United States, EU, Canada as well as Japan in the second half of 2017. Importantly, Mavyret recorded $500 million global sales last year. The initial uptake of the drug has been commendable and we expect its higher sales in the first quarter as well.
Earnings Whispers
Our proven model shows that the stock is likely to beat on earnings this quarter as it has the right combination of the two key ingredients — a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen.
Zacks ESP: AbbViehas an Earnings ESP of +0.06%. The Zacks Consensus Estimate is $1.80 per share. A positive ESP indicates a likely earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: AbbViehas a Zacks Rank #3, which increases the predictive power of ESP and together with a positive ESP, chances of the stock beating estimates in its upcoming release are always pegged higher.
We caution against the Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are a couple of other health care stocks worth considering with the right combination of elements to also surpass estimates this time around:
Pfizer Inc. (PFE - Free Report) is scheduled to release results on May 1. The company has an Earnings ESP of +1.36% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers Squibb Company (BMY - Free Report) is scheduled to report earnings on Apr 26. The company has an Earnings ESP of +0.82% and a Zacks Rank of 3.
Celgene Corporation is slated to announce financial figures on May 4. The company has an Earnings ESP of +0.63% and is a Zacks #3 Ranked player.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>